Estrogen and progesterone receptors are both prognostic and predictive biomarkers in breast cancer. Invasive breast cancers expressing progesterone receptor without estrogen receptor are uncommon, with an incidence of 3.4 to 7 % of all breast cancer cases irrespective of Her2 status. The significance of ER negative / PR positive subgroup has been largely debated, particularly in early breast tumors. The clinicopathologic characteristics, the responsiveness to treatment and the long term outcomes are still not well elucidated. This is a retrospective review of patients with early or locally advanced breast cancer, treated and followed at the American University of Beirut Medical Center, within a period extending from 1 January 2003 until 31 December 2013, in order to know the exact incidence of ER negative/PR positive/Her2 negative subgroup in our population, and analyze the clinicopathologic features, responsiveness to endocrine therapy, relapse free survival and overall survival, in comparison to the triple negative subgroup.
From the pathology records,breast cancer patients with “breast AND carcinoma” diagnosis within a period frame extending from 1 January 2003 until 31 December 2013 will be selected
Clinical characteristics, pathologic data, treatment received, and outcomes will be collected through retrospective chart reviews
Early or locally advanced invasive ductal or lobular breast cancer will be included
Patients with in situ
carcinoma or metastatic disease will be excluded.
Patients treated and followed outside our institution will be excluded.